Please login to the form below

Not currently logged in
Email:
Password:

AZ denies it will outsource drug manufacturing

AstraZeneca responds to a report in the 17 September Times article which claimed that the Anglo-Swedish pharmaceutical company would outsource its drug manufacturing operations over the next 10 years

AstraZeneca (AZ) has responded to a report in the 17 September Times article which claimed that the Anglo-Swedish pharmaceutical company would outsource its drug manufacturing operations over the next 10 years.

AZ's executive vice-president of operations, David Smith, was quoted as saying that manufacturing for AZ was not a core activity and that the company was concerned primarily with innovation and brand-building: "There are lots of people and organisations that can manufacture better than we can."

AZ insists that the original purpose of the Times interview was to discuss how the pharmaceutical industry was looking to other industries for Supply Chain practices and philosophies and that outsourcing supply and manufacturing activities, as implied in the article, was not part of the AZ strategy.

The company will, however, use outsourcing where there is a sound business case. For example, it is currently exploring the manufacture of Active Pharmaceutical Ingredients (API) the basic chemicals used to formulate conventional medicines.

AZ said in a statement: "The delivery of medicines for patients remains top priority for AstraZeneca and our global operations will continue to source activities in-house that are critical to keeping connected with the patient and essential to ensuring patient safety.  Supply and manufacturing will continue to play an important role in this through delivery of a robust end-to-end supply chain."

18th September 2007

Share

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
M3 (EU)

M3 has over 20 years’ experience in building online doctor communities. M3 is the world’s largest network of verified doctors...

Latest intelligence

Shaping the dermatology landscape: Independent expert analysis of the pipeline in 5 disease areas
Leading dermatologists discuss the innovations shaping 5 chronic skin diseases—psoriasis, atopic dermatitis, alopecia areata, vitiligo, and hidradenitis suppurativa—and share the challenges and opportunities for biopharmaceutical companies developing innovative treatments....
Keith Berelowitz
Transforming clinical trials to accelerate drug development
...
How the WHO hepatitis strategy measures up in the field
With hepatitis cases on the rise, Dr Anthony Martinez, member of the International Hepatitis Education Program (IHEP), shares his perspective on the World Health Organization’s new strategy for hepatitis elimination...